⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JAGX News
Jaguar Health, Inc.
Form 8-K
sec.gov
JAGX
Jaguar Health Reports First Quarter 2026 Financials
accessnewswire.com
JAGX
Form 8-K
sec.gov
JAGX
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
accessnewswire.com
JAGX
Form 8-K
sec.gov
JAGX
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
accessnewswire.com
JAGX
Beyond announces major Argentina investment to create 100+ engineering roles and expand global cloud delivery
globenewswire.com
PAY
JAGX
SNAP
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
accessnewswire.com
JAGX
Form 8-K
sec.gov
JAGX
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
accessnewswire.com
JAGX